Compassionate use of <scp>long‐acting</scp> cabotegravir plus rilpivirine for people living with <scp>HIV</scp> ‐1 in need of parenteral antiretroviral therapy-Reference-Cited by-同舟云学术

Compassionate use of long‐acting cabotegravir plus rilpivirine for people living with HIV ‐1 in need of parenteral antiretroviral therapy

Published:2022-08-09 Issue:2 Volume:24 Page:202-211
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Medicine

Author:

D'Amico Ronald¹^ORCID,Cenoz Gomis Santiago²,Moodley Riya³,Van Solingen‐Ristea Rodica⁴,Baugh Bryan⁵,Van Landuyt Erika⁴,Van Eygen Veerle⁴,Min Sherene¹,Cutrell Amy¹,Foster Caroline⁶^ORCID,Chilton Daniella⁷^ORCID,Allard Sabine D.⁸,Ruiter Annemiek³

Affiliation:

1. ViiV Healthcare Durham North Carolina USA

2. ViiV Healthcare Madrid Spain

3. ViiV Healthcare Brentford UK

4. Janssen Pharmaceutica Beerse Belgium

5. Janssen Pharmaceutica Raritan New Jersey USA

6. Imperial College NHS Healthcare Trust London UK

7. Guys and St Thomas NHS Healthcare Trust London UK

8. HIV Reference Center Universitair Ziekenhuis Brussel Brussels Belgium

Funder

ViiV Healthcare

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hiv.13370

Reference17 articles.

1. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

2. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

3. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

4. Cabenuva [prescribing information]. Research Triangle Park NC: ViiV Healthcare; 2022.

5. ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long‐acting regimen for HIV treatment;ViiV Healthcare;ViiV Healthcare, January,2021

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Direct switch from an efavirenz-based regimen to intramuscular long-acting cabotegravir plus rilpivirine: A case report;International Journal of STD & AIDS;2023-11-24

2. Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort;Infectious Diseases and Therapy;2023-11-15

3. A National HIV Provider Survey of Antiretroviral Therapy Preferences for Management of Treatment-Naive and Experienced Individuals With Drug Resistance;Open Forum Infectious Diseases;2023-10-31

4. The New Era of Long-Acting Antiretroviral Therapy: When and Why to Make the Switch;Current HIV/AIDS Reports;2023-09-21

5. A Fractional Perspective on the Dynamics of HIV, Considering the Interaction of Viruses and Immune System with the Effect of Antiretroviral Therapy;Journal of Nonlinear Mathematical Physics;2023-08-05